Clinical trials: Etoposide
Relapsed/Refractory Acute Myeloid Leukemia
Efficacy/Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. in Older Patients With R/R AML
A Phase III study to evaluate the safety and efficacy of CPI-613® (devimistat) in combination with High Dose Cytarabine and Mitoxantrone in comparison with high dose Cytarabine and Mitoxantrone and control sub-groups: combination…
- Trial name
- NCT03504410
- Testing
- CPI-613 + High Dose Cytarabine and Mitoxantrone, High Dose Cytarabine and Mitoxantrone, Mitoxantrone, Etoposide and Cytarabine
- Where
- 60 sites in United States, Australia and 7 more
- Volunteers
- 200 people
- Sponsor
- Cornerstone Pharmaceuticals
Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma
Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma
This phase II trial studies how well combination chemotherapy and pralatrexate works in treating patients with non-Hodgkin lymphoma (NHL).
- Conditions
- Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Hepatosplenic T-cell Lymphoma, Peripheral T-cell Lymphoma
- Trial name
- NCT01336933
- Testing
- prednisone, cyclophosphamide, etoposide
- Where
- 9 sites in United States
- Volunteers
- 34 people
- Sponsor
- University of Nebraska
Myelodysplastic Syndrome, Hodgkin's Lymphoma
Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System
Background: Major problems with stem cell transplantation (SCT) for cancer treatment are a lack of suitable donors for patients without a human leukocyte-antigen (HLA) tissue-matched sibling and graft-versus-host disease (GVHD)…
- Conditions
- Myelodysplastic Syndrome, Hodgkin's Lymphoma, Non-Hodgkin's Disease, Acute Leukemia
- Trial name
- NCT00520130
- Testing
- Rituximab, Cyclosporine, Allogenic stem cell transplant (ASCT)
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- National Cancer Institute (NCI)
Primary Effusion Lymphoma, B-Cell Neoplasm
Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma
Background: Primary effusion lymphoma (PEL) is a rare disease with no standard treatment. Researchers want to see if a drug called lenalidomide along with common chemotherapy drugs may be effective in treating PEL.
- Trial name
- NCT02911142
- Testing
- Lenalidomide, Rituximab, Prednisone
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
B-Cell Lymphoma Originating in the CNS
The Addition of Temozolomide to Conditioning for Autologous Transplantation in Relapsed & Refractory CNS Lymphoma
The primary purpose of the study will be testing the dosing of temozolomide to find the target dose that a person can tolerate. The other part of the study will be determining how helpful it can be to CNS lymphoma patients by…
- Trial name
- DRBEAT (NCT01235793)
- Testing
- Temozolomide
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Cedars-Sinai Medical Center
Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia
High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia
This pilot clinical trial studies the feasibility of choosing treatment based on a high throughput ex vivo drug sensitivity assay in combination with mutation analysis for patients with acute leukemia that has returned after a…
- Conditions
- Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia
- Trial name
- NCT02551718
- Testing
- Chemosensitivity Assay, Cytology Specimen Collection Procedure, Gene Expression Analysis
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of Washington
Limited Stage Small Cell Lung Cancer
Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer
This phase 2 trial examined whether the preliminary efficacy and safety of ociperlimab, tislelizumab, and cCRT when used in combination is expected to advance treatment options in the serious unmet medical need population of…
- Trial name
- NCT04952597
- Testing
- Ociperlimab, Tislelizumab, Concurrent Chemoradiotherapy
- Where
- 33 sites in United States, China and 1 more
- Volunteers
- 126 people
- Sponsor
- BeiGene
Osteosarcoma, Sarcoma, Ewing's
A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720)
Participants with relapsed osteosarcoma that can be treated with surgery will be randomized to robatumumab administered intravenously (IV) at one of two dose levels.
- Conditions
- Osteosarcoma, Sarcoma, Ewing's, Peripheral Neuroectodermal Tumor
- Trial name
- NCT00617890
- Testing
- robatumumab
- Volunteers
- 219 people
- Sponsor
- Merck Sharp & Dohme LLC
Diffuse Large B-cell Lymphoma
New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement
This is an open, non comparative, multicentre phase II trial, to evaluate the efficacy and feasibility of a new sequential combination of HD-MTX-AraC-based chemoimmunotherapy, followed by R-ICE regimen, and by high-dose…
- Trial name
- NCT02329080
- Testing
- Methotrexate, Rituximab, Cytarabine
- Where
- 36 sites in Czechia, Italy and 2 more
- Volunteers
- 79 people
- Sponsor
- International Extranodal Lymphoma Study Group (IELSG)
Neuroblastoma
N2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma
RATIONALE: Radioactive drugs, such as iodine I 131 metaiodobenzylguanidine, may carry radiation directly to tumor cells and not harm normal cells.
- Trial name
- NCT00253435
- Testing
- Filgrastim, Carboplatin, Etoposide
- Where
- 15 sites in United States, Canada
- Volunteers
- 50 people
- Sponsor
- New Approaches to Neuroblastoma Therapy Consortium
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia
A Study of Clofarabine in Combination With Etoposide and Cyclophosphamide in Children With Acute Leukemias.
Clofarabine (injection) is approved by the Food and Drug Administration (FDA) for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia (ALL) who have had at least 2 prior…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Relapsed Leukemia
- Trial name
- NCT00315705
- Testing
- clofarabine, Etoposide, Cyclophosphamide
- Where
- 13 sites in United States
- Volunteers
- 50 people
- Sponsor
- Genzyme, a Sanofi Company
Adult T Acute Lymphoblastic Leukemia, Ann Arbor Stage II Adult Lymphoblastic Lymphoma
Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
This randomized phase III trial compares how well combination chemotherapy works when given with or without bortezomib in treating patients with newly diagnosed T-cell acute lymphoblastic leukemia or stage II-IV T-cell…
- Conditions
- Adult T Acute Lymphoblastic Leukemia, Ann Arbor Stage II Adult Lymphoblastic Lymphoma, Ann Arbor Stage II Childhood Lymphoblastic Lymphoma, Ann Arbor Stage III Adult Lymphoblastic Lymphoma
- Trial name
- NCT02112916
- Testing
- Bortezomib, Cyclophosphamide, Cytarabine
- Where
- 212 sites in United States, Australia and 2 more
- Volunteers
- 847 people
- Sponsor
- National Cancer Institute (NCI)
CD20 Positive, Recurrent Diffuse Large B-Cell Lymphoma
Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma
This phase I/Ib trial studies the side effects and best dose of carfilzomib when given together with rituximab, ifosfamide, carboplatin, and etoposide and to see how well it works in treating patients with stage I-IV diffuse…
- Conditions
- CD20 Positive, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Stage I Diffuse Large B-Cell Lymphoma
- Trial name
- NCT01959698
- Testing
- Carboplatin, Carfilzomib, Etoposide
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Roswell Park Cancer Institute
Lung Cancer, Non-small Cell Carcinoma
Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer
Single arm study of induction durvalumab (1500 mg IV) for 1 cycle (every 4 weeks), administered prior to starting concurrent definitive chemoradiation, followed by consolidation durvalumab (1500 mg IV every 4 weeks) for up to 12…
- Trial name
- NCT04364048
- Testing
- Induction Durvalumab, Chemotherapy, Radiation
- Where
- 5 sites in United States
- Volunteers
- 10 people
- Sponsor
- Rachel Sanborn
Leukemia
Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis
The goal of this clinical research study is to compare the effect of adding either alemtuzumab or tocilizumab to the drug combination of etoposide and dexamethasone in controlling HLH.
- Trial name
- NCT02385110
- Testing
- Alemtuzumab, Etoposide, Dexamethasone
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Acute Lymphoblastic Leukemia
Rituximab for Patients With Relapsed Acute Lymphoblastic Leukemia
This is a pilot study of a drug called rituximab used together with other drugs-prednisone, etoposide, and ifosfamide. Prednisone, etoposide, and ifosfamide have been used as part of standard chemotherapy for relapsed Acute…
- Conditions
- Leukemia, Acute Lymphoblastic Leukemia, ALL
- Trial name
- Rituximab (NCT01230788)
- Testing
- rituximab
- Where
- 3 sites in United States
- Volunteers
- 1 people
- Sponsor
- Emory University
Lymphoma
Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00392834
- Testing
- filgrastim, pegfilgrastim, rituximab
- Where
- 13 sites in United States
- Volunteers
- 34 people
- Sponsor
- AIDS Malignancy Consortium
Lymphoma, Non-Hodgkin
Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma
The purpose of this trial is to develop an alternative treatment for patients with poor risk non-Hodgkin's lymphoma. This trial uses a combination of high dose chemotherapy with stem cell transplant using the patient's own cells.
- Trial name
- NCT00481832
- Testing
- Cyclophosphamide, BCNU, Etoposide
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Stanford University
Multiple Myeloma
UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy
This study has been designed to evaluate whether "anti-angiogenesis" therapy with thalidomide and whether additional chemotherapy after transplant will be beneficial.
- Trial name
- NCT00083551
- Testing
- Thalidomide, Ara-C, BCNU
- Where
- United States
- Volunteers
- 668 people
- Sponsor
- University of Arkansas
Diffuse Large B-Cell Lymphoma
Comparison of HD Chemotherapy Followed by Auto-transplant and R-CHOP in High Risk Patients With DLBCL.
Multicentric randomized phase III study comparing high doses of chemotherapy with Rituximab followed by auto-transplant HPC versus CHOP plus Rituximab as first line therapy in high risk patients with DLBCL Non-Hodgkin's lymphomas.
- Trial name
- NCT00355199
- Testing
- Rituximab-HDS, Rituximab-CHOP
- Where
- 16 sites in Italy
- Volunteers
- 246 people
- Sponsor
- Gruppo Italiano Terapie Innovative nei Linfomi